Lipid-based amphotericin B for the treatment of fungal infections. - Wikidata - wikimedia - TriplyDB

Lipid-based amphotericin B for the treatment of fungal infections.

Lipid-based amphotericin B for the treatment of fungal infections.

http://www.wikidata.org/entity/Q33604227

about

Atrioventricular block related to liposomal amphotericin B.Amphotericin B-induced nephrotoxicity: a review.Intravenous itraconazole.Renal transport of antibiotics and nephrotoxicity: a review.Antimicrobial-associated renal tubular acidosis.Candida endophthalmitis: focus on current and future antifungal treatment options.Amphotericin B use in children: conventional and lipid-based formulations.Fungal endophthalmitis.Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Pharmacokinetics and nephrotoxicity of amphotericin B-incorporated poly(ethylene glycol)-block-poly(N-hexyl stearate l-aspartamide) micelles.Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid.Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins.

P2860

Q33744152-880B80B8-C536-4A2E-A33B-1CF6E343B8C4 Q34128655-2106333C-65F8-4417-B86E-C1A395E5C002 Q34284268-F16BC082-B948-4E17-8D67-87D01FBE4C0F Q34472677-33F5703F-B234-4F6D-98D4-9516A828BC81 Q35758584-6A8507D0-A666-49D5-B55C-F00FDBDBA69B Q37015976-E8525719-3FED-4E0A-8092-926537539989 Q37854727-5660B326-BDBE-4B1B-8204-2DF9FED19778 Q37960568-66CB020C-D8AC-459A-BB15-5D3690DA65BD Q38040820-719DB82E-7C9C-4DE4-A2EA-B57982ADB21E Q38077678-6E4435A4-E1C0-46EE-9F08-9655A2935A98 Q40277812-88EFE263-88EE-492A-B84C-07E5171DDCD6 Q44356131-3DF08176-55D4-4CD6-9C40-306467263BD5 Q44849271-AFDEABFD-6781-4951-BE29-D5E73E896EF6

P2860

Lipid-based amphotericin B for the treatment of fungal infections.

http://www.wikidata.org/entity/Q33604227

description

1999 nî lūn-bûn

@nan

1999 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի մարտին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Lipid-based amphotericin B for the treatment of fungal infections.

@ast

Lipid-based amphotericin B for the treatment of fungal infections.

@en

type

label

Lipid-based amphotericin B for the treatment of fungal infections.

@ast

Lipid-based amphotericin B for the treatment of fungal infections.

@en

prefLabel

Lipid-based amphotericin B for the treatment of fungal infections.

@ast

Lipid-based amphotericin B for the treatment of fungal infections.

@en

P1433

Q33604227-25678CFD-233B-41C8-B9F3-8F378F67104C

P1476

Q33604227-75CEEFA7-7148-4ED4-9D4B-7632E80D01C2

P2093

Q33604227-70F61E16-3AEA-4AB8-87CE-004D2FD872B5

P2860

Q33604227-0092E169-EF7D-4FC9-842B-687BC7C59DAC

Q33604227-0F2E2B40-D442-4823-B530-60982D65177A

Q33604227-16C1C045-8C38-428F-8616-3EEED4FE8A35

Q33604227-172C8A94-C157-42FF-8959-1C601B68B081

Q33604227-21B57972-9F7F-49BB-AE7F-2D0C169650D3

Q33604227-296A639E-3AB3-4517-932C-B67E0F3DC3C1

Q33604227-3ADFF2EB-92DD-475F-8E51-9593699C93F1

Q33604227-3C89DB28-7BBA-42C8-A6F5-DF14606F29AE

Q33604227-43F6C751-0247-45B1-97BA-B04EAB3B7CD8

Q33604227-4C1757C4-E432-4242-BDC9-971DD463C614

P304

Q33604227-DDBE4783-4461-42C3-85EF-695CE93036BE

P31

Q33604227-25AA26FC-433E-4CC6-8633-1D355A42BAFD

P356

Q33604227-6C14593B-75F1-43CB-A6DE-D2A8C6096908

P407

Q33604227-3B9D69B0-3ADA-4CEE-9F7B-E81B013D1E70

P433

Q33604227-D9CA7204-D0E6-4F21-91A7-6C707358E458

P478

Q33604227-0147DEA9-2308-4769-A934-081861E8194B

P577

Q33604227-A3AA79EA-FA6C-4431-8BD2-E8277FAB101B

P698

Q33604227-4463DCC7-11D7-423D-B467-CB9567811045

P356

PHCO.19.4.306.30934

P1433

Pharmacotherapy

P1476

Lipid-based amphotericin B for the treatment of fungal infections.

@en

P2093

Slain D

http://www.w3.org/2001/XMLSchema#string

P2860

Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.

Safety of amphotericin B colloidal dispersion.

Unusual lipid structures selectively reduce the toxicity of amphotericin B.

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.

Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model.

Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

P304

306-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.19.4.306.30934

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

1999-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10221369

http://www.w3.org/2001/XMLSchema#string